Enhertu Gains Approval in China as First HER2-Directed Therapy for HER2-Mutant Metastatic Non-Small Cell Lung Cancer Read more
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation Read more
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment Read more
Boehringer receives FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide Read more
Teva and mAbxience Strengthen Strategic Alliance with New Oncology Biosimilar Candidate Addition Read more
FDA Approves Neoadjuvant Opdivo and Chemotherapy for Resectable Non-Small Cell Lung Cancer Treatment Pathway Read more
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities Read more
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer Read more